Published in Hepatitis Weekly, May 25th, 1998
The study involves 300 patients with chronic hepatitis B infection and is a randomized, double-blind clinical trial using thymosin alpha 1.
"The launch of this trial in Japan is another significant milestone for SciClone and its shareholders," stated Donald R. Sellers, SciClone. "It represents the culmination of over five years of cooperative development and investment and the beginning of the final stage of the Japanese...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (1998-05-25)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.